Aviva
XLRN

Aviva’s Acceleron Pharma XLRN Stock Holding History

Aviva’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-9,029
Closed -$1.22M – 1016
2021
Q1 		$1.22M Sell
9,029
-2,484
-22% -$321K 0.01% 819
2020
Q4 		$1.47M Sell
11,513
-9,333
-45% -$1.09M 0.01% 773
2020
Q3 		$2.35M Sell
20,846
-2,907
-12% -$289K 0.01% 657
2020
Q2 		$2.26M Sell
23,753
-18,680
-44% -$1.8M 0.01% 734
2020
Q1 		$3.81M Sell
42,433
-1,171
-3% -$91K 0.03% 487
2019
Q4 		$2.31M Buy
+43,604
New +$1.99M 0.01% 642

Other funds holding XLRN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Aviva's XLRN Position: Q2 2021 in Review

Aviva sold out of Acceleron Pharma (XLRN) in Q2 2021, closing a stake of 9,029 shares — an estimated $1.22M sold.

Aviva first reported a position in XLRN in Q4 2019 and held it in 6 quarters. The position peaked at $3.81M in Q1 2020. 271 funds tracked by Wall St. Rank hold XLRN as of Q2 2021.

  • Aviva reported no remaining Acceleron Pharma position as of Q2 2021 after selling out during the quarter.
  • Aviva sold 9,029 Acceleron Pharma shares in Q2 2021, an estimated $1.22M.
  • Aviva first reported a position in Acceleron Pharma in Q4 2019 and held it in 6 quarters.
  • Aviva's Acceleron Pharma position peaked at $3.81M in Q1 2020.
  • 271 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2021.

Based on Aviva's 13F filing for Q2 2021, filed 10 Aug 2021.